National Institute of Mental Health (NIMH)

nimh.nih.gov

Total trials

360

Active

43

Phase 3

10

Total enrollment

148,890

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ketamine Hydrochloride1
Fluoxetine4
18F-PF-064459743
11C-PS133
18F-florbetaben2
11C-MC13
Ketamine2
Apremilast1
18F-PF9741
11C-MCI1
11CPS131
Intravenous Ethanol1
11C-JMJ-1291
Arm 1, 2, 3 drug Interventions1
Arm 1 and 2 Interventions1
Lithium3

Next readouts

  • 2027-01-01
  • 2027-02-01
  • 2028-02-22
  • 2028-02-22
  • 2028-02-22
  • 2028-10-03
  • 2028-12-11
  • 2029-01-01
  • 2029-04-11
  • 2029-04-11

Top conditions

  • Healthy63
  • Depression47
  • Bipolar Disorder34
  • Schizophrenia34
  • Major Depressive Disorder18
  • Mood Disorder16
  • Anxiety Disorders14
  • Mood Disorders13

Frequently asked questions about National Institute of Mental Health (NIMH)

How many clinical trials does National Institute of Mental Health (NIMH) have on ClinicalTrials.gov?
National Institute of Mental Health (NIMH) is listed as the lead sponsor on 360 clinical trials in ClinicalTrials.gov, 43 of which are currently active (recruiting, enrolling, or ongoing).
How many of National Institute of Mental Health (NIMH)'s trials are in Phase 3?
10 of National Institute of Mental Health (NIMH)'s trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does National Institute of Mental Health (NIMH) focus on?
National Institute of Mental Health (NIMH)'s most-studied conditions on ClinicalTrials.gov are Healthy, Depression, Bipolar Disorder, Schizophrenia, Major Depressive Disorder.
When are National Institute of Mental Health (NIMH)'s next clinical trial readouts?
National Institute of Mental Health (NIMH) has 10 upcoming primary-completion readouts tracked here; the soonest is “Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder”, expected around 2027-01-01.